VEGFA and hepatocellular carcinoma: Egyptian studies on 45 patients with intermediate HCC showed stable disease in all patients treated with VAE, accompanied by significant angiogenic modulation—increased vascular endothelial growth factor (VEGF) and TNF-α with decreased transforming growth factor-beta (TGF-β) [57].